NEW YORK, NY & PETACH TIKVAH, ISRAEL / ACCESSWIRE / September 24, 2014 / BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market, and hopes to commence trading on the NASDAQ Capital Market when trading begins on September 30, 2014. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.
http://ift.tt/1CjQHwX
http://ift.tt/1CjQHwX
No comments:
Post a Comment